代謝異常治療薬の世界市場インサイト、2029年までの予測Global Metabolic Disorder Therapeutics Market Insights, Forecast to 2029 市場分析・洞察:代謝異常治療薬の世界市場 代謝疾患治療薬の世界市場は、2023年の50150百万米ドルから2029年には64560百万米ドルへと、予測期間中に4.3%の年間平均成長率(CAGR)で成長すると予測されます。 ... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー市場分析・洞察:代謝異常治療薬の世界市場代謝疾患治療薬の世界市場は、2023年の50150百万米ドルから2029年には64560百万米ドルへと、予測期間中に4.3%の年間平均成長率(CAGR)で成長すると予測されます。 代謝性疾患に対する1回限りの治療法に対する需要の高まりと、生活習慣病の有病率の上昇が、この市場の成長を後押しすると予想される主要因です。 レポートには、以下の内容が含まれます。 本レポートでは、代謝異常治療薬の世界市場規模を概観しています。2018年~2022年の過去の市場収益データ、2023年の予測、2029年までのCAGRの予測など、世界市場の動向を分析します。 代謝異常治療薬の主要生産者を調査し、主要地域と国の収益も提供します。代謝異常治療薬の今後の市場可能性と、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国に焦点を当てたハイライトです。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他諸国の国別データおよび市場価値分析。 本レポートでは、2018年から2023年のデータをもとに、代謝異常治療薬の収益、主要企業の市場シェア、業界ランキングに焦点を当てています。世界の代謝異常治療薬市場における主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づき分析します。本レポートは、関係者が競争環境を理解し、より多くの洞察を得て、自社のビジネスと市場戦略をより良い方法で位置づけるのに役立ちます。 本レポートでは、2018年から2029年までの、タイプ別、用途別のセグメントデータ、収益、成長率を分析しています。代謝異常治療薬の収益、予測される成長動向、生産技術、用途、エンドユーザー産業の市場規模を評価・予測します。 Novo Nordisk A/S、Sanofi S.A.、Boehringer Ingelheim GmbH、Eli Lilly and Company、Merck KgaA、Amgen, Inc、AstraZeneca PLC、Actelion Pharmaceuticals Ltd、Shire PLCなどの世界の主要企業の記述的企業プロファイル。 会社別 ノボノルディスクA/S サノフィS.A. ベーリンガーインゲルハイムGmbH イーライリリー・アンド・カンパニー メルクKgaA アムジェン社 アストラゼネカPLC アクテリオン・ファーマシューティカルズ・リミテッド シャイアーPLC アッヴィー社(AbbVie, Inc. バイオコン社(Biocon Ltd. バイオマリン・ファーマシューティカルズ・インク ブリストル・マイヤーズ スクイブ・カンパニー シプラ社(Cipla, Inc. サイマベイ・セラピューティクス社 タイプ別セグメント ライソゾーム貯蔵疾患 糖尿病 肥満 遺伝性代謝異常症(Inherited Metabolic Disorders 高コレステロール血症 用途別セグメント オーラル 非経口 その他 地域別 北アメリカ ユーエスエー カナダ ヨーロッパ ドイツ フランス 連邦王国 イタリア ロシア 北欧諸国 その他のヨーロッパ アジア太平洋 中国 日本 南朝鮮 東南アジア インド オーストラリア その他のアジア ラテンアメリカ メキシコ ブラジル ラテンアメリカの残りの地域 中近東・アフリカ・中南米 トルコ サウジアラビア UAE MEAの残りの地域 章立て 第1章:報告書のスコープ、異なる市場セグメント(製品タイプ、アプリケーションなど)のエグゼクティブサマリー、各市場セグメントの市場規模、将来の発展可能性などを紹介します。市場の現状と、短・中期・長期的にどのような進化を遂げる可能性があるのかについて、ハイレベルな視点で解説しています。 第2章 代謝障害治療薬の世界および地域レベルでの収益。各地域とその主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、生産能力などを紹介しています。また、市場力学、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析などを紹介します。 第3章:代謝異常治療薬企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。 第4章:各種市場セグメントを種類別に分析し、各市場セグメントの収益、発展可能性を網羅し、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのに役立つ情報を提供します。 第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、開発可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。 第6章:北米:タイプ別、アプリケーション別、国別、各セグメント別の収益。 第7章:ヨーロッパ:タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第8章:中国 タイプ別、アプリケーション別、セグメント別の収益。 第9章:アジア(中国を除く) タイプ別、アプリケーション別、地域別、各セグメントごとの収益。 第10章 中東、アフリカ、中南米 タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第11章:主要企業のプロフィールを提供し、製品の説明や仕様、代謝異常治療薬の収益、粗利益率、最近の開発など、市場の主要企業の基本状況を詳しく紹介する。 第12章 アナリストの視点/結論 目次1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Lysosomal Storage Diseases 1.2.3 Diabetes 1.2.4 Obesity 1.2.5 Inherited Metabolic Disorders 1.2.6 Hypercholesterolemia 1.3 Market by Application 1.3.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Oral 1.3.3 Parenteral 1.3.4 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Metabolic Disorder Therapeutics Market Perspective (2018-2029) 2.2 Global Metabolic Disorder Therapeutics Growth Trends by Region 2.2.1 Metabolic Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2018-2023) 2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2024-2029) 2.3 Metabolic Disorder Therapeutics Market Dynamics 2.3.1 Metabolic Disorder Therapeutics Industry Trends 2.3.2 Metabolic Disorder Therapeutics Market Drivers 2.3.3 Metabolic Disorder Therapeutics Market Challenges 2.3.4 Metabolic Disorder Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Metabolic Disorder Therapeutics by Players 3.1.1 Global Metabolic Disorder Therapeutics Revenue by Players (2018-2023) 3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2018-2023) 3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Metabolic Disorder Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio 3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2022 3.5 Global Key Players of Metabolic Disorder Therapeutics Head office and Area Served 3.6 Global Key Players of Metabolic Disorder Therapeutics, Product and Application 3.7 Global Key Players of Metabolic Disorder Therapeutics, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Metabolic Disorder Therapeutics Breakdown Data by Type 4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2018-2023) 4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2024-2029) 5 Metabolic Disorder Therapeutics Breakdown Data by Application 5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2018-2023) 5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Metabolic Disorder Therapeutics Market Size (2018-2029) 6.2 North America Metabolic Disorder Therapeutics Market Size by Type 6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 6.2.3 North America Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 6.3 North America Metabolic Disorder Therapeutics Market Size by Application 6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 6.3.3 North America Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 6.4 North America Metabolic Disorder Therapeutics Market Size by Country 6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 6.4.3 North America Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 6.4.4 U.S. 6.4.5 Canada 7 Europe 7.1 Europe Metabolic Disorder Therapeutics Market Size (2018-2029) 7.2 Europe Metabolic Disorder Therapeutics Market Size by Type 7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 7.2.3 Europe Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 7.3 Europe Metabolic Disorder Therapeutics Market Size by Application 7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 7.3.3 Europe Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 7.4 Europe Metabolic Disorder Therapeutics Market Size by Country 7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 7.4.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Metabolic Disorder Therapeutics Market Size (2018-2029) 8.2 China Metabolic Disorder Therapeutics Market Size by Type 8.2.1 China Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 8.2.2 China Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 8.2.3 China Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 8.3 China Metabolic Disorder Therapeutics Market Size by Application 8.3.1 China Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 8.3.2 China Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 8.3.3 China Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Metabolic Disorder Therapeutics Market Size (2018-2029) 9.2 Asia Metabolic Disorder Therapeutics Market Size by Type 9.2.1 Asia Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 9.2.2 Asia Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 9.2.3 Asia Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 9.3 Asia Metabolic Disorder Therapeutics Market Size by Application 9.3.1 Asia Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 9.3.2 Asia Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 9.3.3 Asia Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 9.4 Asia Metabolic Disorder Therapeutics Market Size by Region 9.4.1 Asia Metabolic Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Metabolic Disorder Therapeutics Market Size by Region (2018-2023) 9.4.3 Asia Metabolic Disorder Therapeutics Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type 10.2.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application 10.3.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country 10.4.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Novo Nordisk A/S 11.1.1 Novo Nordisk A/S Company Details 11.1.2 Novo Nordisk A/S Business Overview 11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction 11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.1.5 Novo Nordisk A/S Recent Developments 11.2 Sanofi S.A. 11.2.1 Sanofi S.A. Company Details 11.2.2 Sanofi S.A. Business Overview 11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction 11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.2.5 Sanofi S.A. Recent Developments 11.3 Boehringer Ingelheim GmbH 11.3.1 Boehringer Ingelheim GmbH Company Details 11.3.2 Boehringer Ingelheim GmbH Business Overview 11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction 11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.3.5 Boehringer Ingelheim GmbH Recent Developments 11.4 Eli Lilly and Company 11.4.1 Eli Lilly and Company Company Details 11.4.2 Eli Lilly and Company Business Overview 11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction 11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.4.5 Eli Lilly and Company Recent Developments 11.5 Merck KgaA 11.5.1 Merck KgaA Company Details 11.5.2 Merck KgaA Business Overview 11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction 11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.5.5 Merck KgaA Recent Developments 11.6 Amgen, Inc. 11.6.1 Amgen, Inc. Company Details 11.6.2 Amgen, Inc. Business Overview 11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction 11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.6.5 Amgen, Inc. Recent Developments 11.7 AstraZeneca PLC 11.7.1 AstraZeneca PLC Company Details 11.7.2 AstraZeneca PLC Business Overview 11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction 11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.7.5 AstraZeneca PLC Recent Developments 11.8 Actelion Pharmaceuticals Ltd. 11.8.1 Actelion Pharmaceuticals Ltd. Company Details 11.8.2 Actelion Pharmaceuticals Ltd. Business Overview 11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction 11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.8.5 Actelion Pharmaceuticals Ltd. Recent Developments 11.9 Shire PLC 11.9.1 Shire PLC Company Details 11.9.2 Shire PLC Business Overview 11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction 11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.9.5 Shire PLC Recent Developments 11.10 AbbVie, Inc. 11.10.1 AbbVie, Inc. Company Details 11.10.2 AbbVie, Inc. Business Overview 11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction 11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.10.5 AbbVie, Inc. Recent Developments 11.11 Biocon Ltd. 11.11.1 Biocon Ltd. Company Details 11.11.2 Biocon Ltd. Business Overview 11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction 11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.11.5 Biocon Ltd. Recent Developments 11.12 BioMarin Pharmaceutical, Inc. 11.12.1 BioMarin Pharmaceutical, Inc. Company Details 11.12.2 BioMarin Pharmaceutical, Inc. Business Overview 11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction 11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.12.5 BioMarin Pharmaceutical, Inc. Recent Developments 11.13 Bristol-Myers Squibb Company 11.13.1 Bristol-Myers Squibb Company Company Details 11.13.2 Bristol-Myers Squibb Company Business Overview 11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction 11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.13.5 Bristol-Myers Squibb Company Recent Developments 11.14 Cipla, Inc. 11.14.1 Cipla, Inc. Company Details 11.14.2 Cipla, Inc. Business Overview 11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction 11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.14.5 Cipla, Inc. Recent Developments 11.15 CymaBay Therapeutics, Inc. 11.15.1 CymaBay Therapeutics, Inc. Company Details 11.15.2 CymaBay Therapeutics, Inc. Business Overview 11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction 11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.15.5 CymaBay Therapeutics, Inc. Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
SummaryMarket Analysis and Insights: Global Metabolic Disorder Therapeutics Market Table of Contents1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Lysosomal Storage Diseases 1.2.3 Diabetes 1.2.4 Obesity 1.2.5 Inherited Metabolic Disorders 1.2.6 Hypercholesterolemia 1.3 Market by Application 1.3.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Oral 1.3.3 Parenteral 1.3.4 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Metabolic Disorder Therapeutics Market Perspective (2018-2029) 2.2 Global Metabolic Disorder Therapeutics Growth Trends by Region 2.2.1 Metabolic Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2018-2023) 2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2024-2029) 2.3 Metabolic Disorder Therapeutics Market Dynamics 2.3.1 Metabolic Disorder Therapeutics Industry Trends 2.3.2 Metabolic Disorder Therapeutics Market Drivers 2.3.3 Metabolic Disorder Therapeutics Market Challenges 2.3.4 Metabolic Disorder Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Metabolic Disorder Therapeutics by Players 3.1.1 Global Metabolic Disorder Therapeutics Revenue by Players (2018-2023) 3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2018-2023) 3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Metabolic Disorder Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio 3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2022 3.5 Global Key Players of Metabolic Disorder Therapeutics Head office and Area Served 3.6 Global Key Players of Metabolic Disorder Therapeutics, Product and Application 3.7 Global Key Players of Metabolic Disorder Therapeutics, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Metabolic Disorder Therapeutics Breakdown Data by Type 4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2018-2023) 4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2024-2029) 5 Metabolic Disorder Therapeutics Breakdown Data by Application 5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2018-2023) 5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Metabolic Disorder Therapeutics Market Size (2018-2029) 6.2 North America Metabolic Disorder Therapeutics Market Size by Type 6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 6.2.3 North America Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 6.3 North America Metabolic Disorder Therapeutics Market Size by Application 6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 6.3.3 North America Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 6.4 North America Metabolic Disorder Therapeutics Market Size by Country 6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 6.4.3 North America Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 6.4.4 U.S. 6.4.5 Canada 7 Europe 7.1 Europe Metabolic Disorder Therapeutics Market Size (2018-2029) 7.2 Europe Metabolic Disorder Therapeutics Market Size by Type 7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 7.2.3 Europe Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 7.3 Europe Metabolic Disorder Therapeutics Market Size by Application 7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 7.3.3 Europe Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 7.4 Europe Metabolic Disorder Therapeutics Market Size by Country 7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 7.4.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Metabolic Disorder Therapeutics Market Size (2018-2029) 8.2 China Metabolic Disorder Therapeutics Market Size by Type 8.2.1 China Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 8.2.2 China Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 8.2.3 China Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 8.3 China Metabolic Disorder Therapeutics Market Size by Application 8.3.1 China Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 8.3.2 China Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 8.3.3 China Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Metabolic Disorder Therapeutics Market Size (2018-2029) 9.2 Asia Metabolic Disorder Therapeutics Market Size by Type 9.2.1 Asia Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 9.2.2 Asia Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 9.2.3 Asia Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 9.3 Asia Metabolic Disorder Therapeutics Market Size by Application 9.3.1 Asia Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 9.3.2 Asia Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 9.3.3 Asia Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 9.4 Asia Metabolic Disorder Therapeutics Market Size by Region 9.4.1 Asia Metabolic Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Metabolic Disorder Therapeutics Market Size by Region (2018-2023) 9.4.3 Asia Metabolic Disorder Therapeutics Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type 10.2.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application 10.3.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country 10.4.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Novo Nordisk A/S 11.1.1 Novo Nordisk A/S Company Details 11.1.2 Novo Nordisk A/S Business Overview 11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction 11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.1.5 Novo Nordisk A/S Recent Developments 11.2 Sanofi S.A. 11.2.1 Sanofi S.A. Company Details 11.2.2 Sanofi S.A. Business Overview 11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction 11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.2.5 Sanofi S.A. Recent Developments 11.3 Boehringer Ingelheim GmbH 11.3.1 Boehringer Ingelheim GmbH Company Details 11.3.2 Boehringer Ingelheim GmbH Business Overview 11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction 11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.3.5 Boehringer Ingelheim GmbH Recent Developments 11.4 Eli Lilly and Company 11.4.1 Eli Lilly and Company Company Details 11.4.2 Eli Lilly and Company Business Overview 11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction 11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.4.5 Eli Lilly and Company Recent Developments 11.5 Merck KgaA 11.5.1 Merck KgaA Company Details 11.5.2 Merck KgaA Business Overview 11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction 11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.5.5 Merck KgaA Recent Developments 11.6 Amgen, Inc. 11.6.1 Amgen, Inc. Company Details 11.6.2 Amgen, Inc. Business Overview 11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction 11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.6.5 Amgen, Inc. Recent Developments 11.7 AstraZeneca PLC 11.7.1 AstraZeneca PLC Company Details 11.7.2 AstraZeneca PLC Business Overview 11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction 11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.7.5 AstraZeneca PLC Recent Developments 11.8 Actelion Pharmaceuticals Ltd. 11.8.1 Actelion Pharmaceuticals Ltd. Company Details 11.8.2 Actelion Pharmaceuticals Ltd. Business Overview 11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction 11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.8.5 Actelion Pharmaceuticals Ltd. Recent Developments 11.9 Shire PLC 11.9.1 Shire PLC Company Details 11.9.2 Shire PLC Business Overview 11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction 11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.9.5 Shire PLC Recent Developments 11.10 AbbVie, Inc. 11.10.1 AbbVie, Inc. Company Details 11.10.2 AbbVie, Inc. Business Overview 11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction 11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.10.5 AbbVie, Inc. Recent Developments 11.11 Biocon Ltd. 11.11.1 Biocon Ltd. Company Details 11.11.2 Biocon Ltd. Business Overview 11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction 11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.11.5 Biocon Ltd. Recent Developments 11.12 BioMarin Pharmaceutical, Inc. 11.12.1 BioMarin Pharmaceutical, Inc. Company Details 11.12.2 BioMarin Pharmaceutical, Inc. Business Overview 11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction 11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.12.5 BioMarin Pharmaceutical, Inc. Recent Developments 11.13 Bristol-Myers Squibb Company 11.13.1 Bristol-Myers Squibb Company Company Details 11.13.2 Bristol-Myers Squibb Company Business Overview 11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction 11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.13.5 Bristol-Myers Squibb Company Recent Developments 11.14 Cipla, Inc. 11.14.1 Cipla, Inc. Company Details 11.14.2 Cipla, Inc. Business Overview 11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction 11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.14.5 Cipla, Inc. Recent Developments 11.15 CymaBay Therapeutics, Inc. 11.15.1 CymaBay Therapeutics, Inc. Company Details 11.15.2 CymaBay Therapeutics, Inc. Business Overview 11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction 11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023) 11.15.5 CymaBay Therapeutics, Inc. Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
QYResearch 社の最新刊レポート本レポートと同じKEY WORD(therapeutics)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/12 10:27 143.85 円 158.71 円 190.22 円 |